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Abstract: Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease and the
number of patients affected is increasing worldwide. Thus, there is a need to establish a new
treatment for DKD to improve the renal prognosis of diabetic patients. Recently, it has shown
that intracellular metabolic abnormalities are involved in the pathogenesis of DKD. In particular,
the activity of mechanistic target of rapamycin complex 1 (mTORC1), a nutrient-sensing signaling
molecule, is hyperactivated in various organs of diabetic patients, which suggests the involvement
of excessive mTORC1 activation in the pathogenesis of diabetes. In DKD, hyperactivated mTORC1
may be involved in the pathogenesis of podocyte damage, which causes proteinuria, and tubular
cell injury that decreases renal function. Therefore, elucidating the role of mTORC1 in DKD and
developing new therapeutic agents that suppress mTORC1 hyperactivity may shed new light on
DKD treatments in the future.
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1. Introduction
Diabetic kidney disease (DKD) is one of the most serious complications of diabetes
and the leading cause of end-stage renal disease worldwide. The number of patients with
DKD is increasing and new therapeutic agents for DKD are urgently needed. The typical
clinical course of DKD begins with microalbuminuria, followed by severe proteinuria,
which induces tubular damage and eventually leads to a decline in renal function and end-
stage renal disease (Figure 1a). In recent years, there has been an increase in the number of
diabetic patients who present with decreased renal function without proteinuria [1–3]. This
condition is thought to involve background factors such as aging and atherosclerosis, and
may be different from the typical DKD condition. In clinical practice, the lack of an effective
treatment for DKD with refractory proteinuria and the increasing number of patients with
new forms of DKD who do not present with proteinuria but with reduced renal function
are thought to be contributing factors to the increasing number of patients with DKD that
leads to end-stage renal failure. Thus, there is a need to elucidate the pathogenesis of
refractory proteinuria, the mechanism of progression from refractory proteinuria to renal
function decline, and the pathogenesis of renal function decline without proteinuria.
The pathogenesis of DKD is extremely complex (Figure 1a). The mechanism of renal
glomerular cell damage under diabetic conditions has been considered to be hyperglycemia-
induced metabolic abnormalities and hemodynamic abnormalities such as hyperfiltra-
tion due to systemic and glomerular hypertension associated with a hyperactive renin–
angiotensin system (RAS) [4–7]. Hyperglycemia-induced activation of the polyol pathway,
protein kinase C, hexosamine pathway, oxidative stress, and excessive production of
advanced glycation end-products act cytotoxically to induce glomerular damage, glomeru-
losclerosis, and tubular damage. Additionally, the mechanism of DKD is thought to not
only involve the abovementioned factors, but also dyslipidemia, hyperinsulinemia, and
obesity, as well as multiple factors such as environmental and genetic factors [8–11]. It
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has been reported that microinflammation triggered by abnormal fatty acid metabolism,
endothelial damage, oxidative stress, decreased autophagy activity, and hypoxia in renal
tissue are involved in the development and progression of DKD [12–17].
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Accumulating evidence has demonstrated the relationship between alterations in nu-
trient-sensing signals and DKD progression [8,18,19]. Thus far, we have focused on mech-
anistic target of rapamycin complex 1 (mTORC1) as a pathway involved in the pathogen-
esis of DKD. mTOR is a protein kinase conserved in all species from yeasts to mammals, 
which was discovered in yeast as a binding protein for rapamycin. It forms at least two 
complexes (mTORC1 and mTORC2) with different binding proteins, each of which per-
forms different functions by phosphorylating different substrates. Growth factors such as 
insulin, amino acids, and sugars increase mTORC1 activity, and increased mTORC2 ac-
tivity is mainly regulated by growth factor stimulation. By phosphorylating its substrates, 
mTORC1 promotes cell differentiation and growth, enhances intracellular anabolism, and 
inhibits catabolism such as autophagy [20,21]. mTORC2 phosphorylates and activates 
other kinases mainly as a substrate to promote cytoskeletal reorganization and cell prolif-
eration and inhibit cell death [22]. Interestingly, mTORC1 causes the functional suppres-
sion of adaptor proteins that play important roles downstream of insulin receptors and 
insulin-like growth factor receptors, which is a cause of insulin resistance [23–25] (Figure 
2). 
The increase in the intracellular glucose concentration due to hyperglycemia sup-
presses AMP kinase activity and activates mTORC1. In addition to hyperglycemia, obe-
sity, and type 2 diabetes, hyperinsulinemia and excess amino acids associated with over-
eating are factors required for increased mTORC1 activity, which is observed not only in 
the kidneys [26–28] but also in other organs such as adipose tissue and the liver [29–32]. 
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system (RAS) and hyperfiltration are involved in the progression of DKD. DKD progresses from normoalbuminuria to
microalbuminuria and macroalbuminuria, and the tubulointerstitial lesion to renal dysfunction and end-stage renal failure.
In recent years, the number of patients with a decreased glomerular filtration rate (GFR) without proteinuria has increased,
and aging and atherosclerosis are thought to be involved in the decrease in GFR. Furthermore, mTORC1 activity, which
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cc ulating evidence has demons rated the relationship between alteratio s in
nutrient- e sin signals and DKD progression [8,18,19]. Thus far, we have f cus d on
mechanistic target of rapamycin complex 1 (mTORC1) as a pathway involved in the
pathogenesis of DKD. mTOR is a protei kinase conserved in all sp cie fro yeasts to
mammals, which was discovered in yeast as a b ding protein for rapamycin. It forms
at least two complexes (mTORC1 and mTORC2) with differen binding proteins, each of
which performs differe t functi ns by phosphorylati g diffe ent substra es. Gr wth factors
such as insulin, amino acids, and sugars increase mTORC1 activity, and increased mTORC2
activity is mainly regulated by growth factor stimulation. By phosphorylating its substrates,
r tes ce l di ferentiation and growth, enhances intracellular anabolism, and
t lis such as autophagy [20,21]. mTORC2 phosphorylates and activa es other
kinases mainly s a substrate o promote cytoskeletal r organization and cell pro iferation
and i hibit cell death [22]. Interestingly, mTORC1 causes the functio al suppression of
adaptor proteins that play important roles downstream of insulin receptors and insulin-like
growth facto receptors, which is a cause of insulin resistance [23–25] (Figure 2).
The increase in the intracellular glucose concentration due to hyperglycemia sup-
presses AMP kinase activity nd activates mTORC1. In addition to hyperglycemia, obesity,
and type 2 diabetes, hyperinsulinemia and excess ami o acids ass ciated with over-eating
are f ctors r quired for incr ased mTORC1 activity, which is observed not only in the
kid eys [26–28] but also in ther organs such as adipose tissue and the liver [29–32]. Exces-
sive mTORC1 upregulation can lead to the dysregul tion of intracellular protein synthesis
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and the metabolic balance, which increases endoplasmic reticulum stress and intracellular
oxidative stress (Figure 2).
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In this review, we describe the pathogenesis of DKD by focusing on mTORC1 hyper-
activation and discuss the therapeutic potential of mTORC1 suppression for DKD.
2. Podocyte Injury in Typical DKD and mTORC1
The main caus of proteinur a is the dis uption of he glomerular filtration barrier
function. The glomerular filtration barrier consists of three layers: vascular endo helial
cells, glom ular basement membrane, and podocytes. In particular, podocytes are highly
differentiated terminal y differentiated cells that form a foot structu e between neighboring
cells and play an impor ant rol in the glomerular filtration barrier function. Additionally,
podocytes h ve almost no proliferative activity and it is thought that nce they are damaged
they directly contribute to the failure of the glomerular barrier function.
The hyperactivation of mTORC1 is obs rved in DKD podocytes, which causes cytotox-
icity. It has been reported that the mTORC1 activity increases in the podocytes of diabetic
mice and rats [15,26,27,33]. Podocyte-specific Raptor, an essential protein for mTORC1,
heterozygous mice with suppressed mTORC1 activity, show reduced urinary proteins in
both STZ-induced type 1 diabetic mice [26] and type 2 diabetic db/db mice [27]. It has also
been reported that podocyte-specific mTORC1 hyperactivity odel mice with podocyte-
specific deletion of tuberous sclerosis complex 1, a protein that suppresses mTORC1, show
podocyte damage, proteinuria, and an increased mesangial area similar to the glomerular
lesions caused by DKD [27].
Furthermore, mTORC1 negatively regulates autophagy, an intracellular catabolic
process. Autophagy degrades damaged organelles and proteins, which is triggered by
stress and starvation. Autophagy is necessary to maintain cellular homeostasis. It has
been shown that autophagy decreases in the podocytes of DKD patients with massive
proteinuria [15]. Furthermore, mice with podocyte-specific autophagy deficiency have
severe podocyte damage and massive proteinuria under diabetic conditions [15]. These
findings suggest that decreased podocyte autophagy induces podocyte dysfunction and
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is involved in the progression of DKD. The maintenance of proper autophagy activity in
podocytes by mTORC1 correction may be protective for DKD podocytes (Figure 1b).
3. Tubular Cell Injury in Typical DKD and mTORC1
In glomerular diseases including DKD, a large amount of urinary proteins leaked from
the glomerulus is reabsorbed by the proximal tubules, which overloads the tubular cells and
induces inflammation and fibrosis of the tubular interstitium, ultimately leading to declines
in renal function (Figure 1a). Interestingly, autophagy is induced in proximal tubular cells
by reabsorption of albumin in mice [16]. Additionally, mTORC1 is activated in proximal
tubular cells of obese type 2 diabetic mice fed a high-fat diet, which suppresses autophagy
induced by urinary proteins [16]. In diabetic proximal tubular cells, the cytoprotective
autophagy induced by urinary proteins is suppressed by the activation of mTORC1. As a
result, susceptibility to urinary protein-associated cytotoxicity is induced. Rapamycin, an
mTORC1 inhibitor, suppresses excessive mTORC1 activity and inhibits tubular cell damage
in obese type 2 diabetic mice fed a high fat diet [16]. Moreover, the activation of the mTOR
pathway is involved in the increased expression of profibrotic cytokines, such as TGF-β1
and connective tissue growth factor, and subsequent interstitial fibrosis of DKD [34,35].
Furthermore, proximal tubular cell-specific Raptor heterozygous-deficient mice exhibit
reduced tubular fibrosis and reduced renal function under diabetic conditions [36]. These
results suggest that the abnormal activation of mTORC1 is involved in the pathogenesis of
tubular damage in DKD. Therefore, correcting abnormal intracellular nutrient signaling,
including the suppression of mTORC1, is expected to be a new therapeutic target for the
tubulointerstitial lesion in DKD (Figure 1b).
4. Non-Proteinuric DKD and mTORC1
In recent years, many patients with impaired renal function due to diabetes mellitus
have shown a decreased GFR without microalbuminuria or proteinuria [1,2]. It has been
speculated that arteriosclerotic and tubulointerstitial lesions due to aging and hypertension
exist in the background of these patients (Figure 1a). Strict glycemic control and hyper-
tension treatment with renin-angiotensin system inhibitors have prevented the typical
progression of DKD from microalbuminuria to proteinuria, tubular damage, and renal
function declines [37]. This is thought to be the result of the successful implementation
of evidence-based multidisciplinary treatment, as inferred from the number of patients
on dialysis due to their diabetes having leveled off. However, a large number of new
patients with diabetes mellitus remain on dialysis. There are interesting reports on the
clinical picture of DKD patients in recent years. A review of diabetic patients for several
decades showed that, although the incidence of albuminuria has decreased, the percentage
of patients with reduced eGFR has increased [1]. This observation suggests that, while the
progression of renal damage caused by typical DKD, which is triggered by proteinuria due
to glomerular lesions, has been decreasing, the effect of the involvement of nephrosclerosis
related to aging, hypertension, and arteriosclerosis on GFR decline has been increasing
(Figure 1a). Therefore, it is necessary to clarify the pathogenesis of both types of DKD to
develop treatment strategies for DKD.
In a study of cultured cells, the mTORC1 activity in cultured tubular cells was
suppressed by hypoxic stimuli, but the coadministration of diabetes-like stimuli (hy-
perglycemia and a high concentration of palmitic acid) under hypoxic conditions increased
mTORC1 activity in the cells, which led to cell death. Furthermore, this cell death was in-
hibited significantly by the addition of rapamycin [38]. These results suggest that mTORC1,
which should be suppressed under hypoxic conditions such as atherosclerosis, is exces-
sively upregulated in the diabetic state with hypoxia and this may be involved in cell
damage. Additionally, ApoE-deficient high fat diet-overloaded mice exhibit atheroscle-
rosis, tubular damage without proteinuria, and reduced renal function, which have been
reported to be useful as a DKD model without proteinuria. In these mice, tubular cells
show tubular damage and the hyperactivation of tubular mTORC1 [39]. Furthermore,
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administration of ketone bodies or SGLT2 inhibitors suppresses mTORC1 hyperactiva-
tion in tubules and reduces tubular damage [39]. These findings suggest that excessive
mTORC1 activation is involved in the pathogenesis of DKD even in non-proteinuric DKD
(Figure 1a). Therefore, mTORC1 suppression may be effective to inhibit the development
and progression of non-proteinuric DKD.
5. Oxidative Stress and mTORC1
Oxidative stress is a major factor in the pathogenesis of DKD. In the diabetic state,
hyperglycemia enhances the production of reactive oxygen species (ROS) in the kidneys.
Intracellular metabolic abnormalities, such as hyperglycemia-induced enhancement of
the polyol pathway, protein kinase C activation, and the accumulation of intracellular
glycated proteins, have been implicated in the increase in ROS in diabetic kidneys [40,41].
High levels of free fatty acids (FFAs) may also stimulate ROS generation under diabetic
conditions [42,43]. Moreover, the accumulation of damaged mitochondria in diabetic
kidneys contributes to ROS generation [44,45]. Increased oxidative stress indices in blood
and urine have been reported in diabetic patients and animals [46–49], and there have
been many reports that suggest an increase in oxidative stress in renal tissues. In STZ rats,
studies have reported an increase in the content of 8-hydroxydeoxyguanosine (8-OHdG),
an indicator of oxidative stress, in renal tissue, an increase in urinary 8-OHdG excretion,
and a significant increase in the 8-OHdG content of mitochondrial DNA in renal tissue [50].
Increased urinary 8-OHdG excretion and increased mitochondrial oxidative damage in
renal tissue have also been reported in db/db mice [51]. mTORC1 signaling and oxidative
stress are closely related to each other. Insulin resistance induced by excessive mTORC1
activation promotes ROS synthesis. Furthermore, autophagy plays an important role
in maintaining mitochondrial functions. Mitochondrial quality control is mediated by
mitochondrial autophagy (mitophagy) [52–54]. Oxidative stress also induces autophagy
to remove damaged mitochondria in an attempt to protect the cell. Thus, autophagy-
mediated mitochondrial quality control and the subsequent reduction in ROS may be
essential to protect the kidneys of diabetic patients. Therefore, upon autophagy suppression
by inappropriate mTORC1 hyperactivation, the decrease in autophagy activity decreases
intracellular organelle and mitochondrial functions, which in turn increases oxidative
stress (Figure 2). These findings suggest that suppression of excessive mTORC1 activity in
diabetic patients may also decrease ROS (Figure 1b).
6. Clinical Use and Adverse Effects of mTOR Inhibitors
Several studies have reported the inhibitory effect of rapamycin on the development
and progression of DKD in diabetic animal models [34,55–59]. In fact, rapamycin is widely
used clinically as an anti-cancer drug and post-transplantation immunosuppressive agent,
which may have potential as a DKD treatment. However, it is also true that many side
effects have been reported with rapamycin [60]. It has been reported to cause nephrotoxic-
ity, such as increased urinary protein [61], acute tubular necrosis [62], and FSGS [63], as
well as metabolic abnormalities such as insulin resistance, glucose intolerance [64,65], and
abnormal lipid metabolism [21,66]. mTOR plays an important role also in the maintenance
of immune cell function, and the administration of rapamycin may affect immune function
against infections [67]. Moreover, the long-term administration of rapamycin suppresses
not only mTORC1, but also mTORC2 [68], and the attenuation of AKT activity by mTORC2
suppression may impair the functional maintenance of podocytes under disease or stress
conditions [69]. Interestingly, mTORC2 inhibition rather than mTORC1 inhibition has
been reported to be involved in the pathogenesis of insulin resistance and dyslipidemia by
rapamycin [70–72]. These suggests that a more mTORC1-specific inhibitor may be a safer
therapeutic agent for DKD. Furthermore, Pod-Raptor KO mice, in which mTORC1 activity
is severely suppressed in podocytes, show structural abnormalities in foot processes and
severe proteinuria [26]. Tubular cell-specific Raptor KO mice show impairment of endocyto-
sis and nutrient transport [73]. These findings indicate that physiological mTORC1 activity
Antioxidants 2021, 10, 321 6 of 9
is essential for the normal function of podocytes and tubular cells. When considering the
suppression of mTORC1 as a new therapeutic approach for DKD, it is desirable to develop
safe mTORC1 modulators in the future.
7. Conclusions
It is expected that a therapeutic approach that focuses on mTORC1 as a new thera-
peutic target for DKD will be promising. Rapamycin itself, an mTORC1 inhibitor, was
discovered more than 40 years ago, but in recent years there has been growing interest in
its pathways and new clinical applications. It is desirable to develop mTORC1 inhibitors
that are more mTORC1-specific and that make it easier to regulate mTORC1 activity for
clinical application as DKD therapeutics.
In summary, although there are several problems to be resolved, we believe that
the correction of abnormalities in nutrient-sensing signals such as the hyperactivation of
mTORC1 will become a new treatment strategy for DKD.
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